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Abstract: Infections caused by vancomycin-resistant enterococci (VRE) may be difﬁ  cult to 
treat because of the limited armamentarium of antimicrobial agents. The difﬁ  culty is com-
pounded in pediatric patients in general and neonates in particular because many of the newer 
antimicrobials have not been studied or approved for children. We report a 3-week-old infant 
who developed enterococcal bacteremia on post-operative day 10 after a surgical palliation for 
complex congenital heart disease that was complicated by acute renal failure. Despite removal 
of vascular catheters and antimicrobial regimens that included linezolid, quinupristin/dalfopristin, 
ampicillin/sulbactam, rifampin, and gentamicin, bacteremia persisted. It was not cleared until 
daptomycin (in combination with doxycycline) was started. This is the ﬁ  rst case of successful 
treatment of probable endocarditis due to VRE in a neonate using a daptomycin-containing 
regimen.
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Introduction
Daptomycin is a semisynthetic cyclic lipopeptide antibiotic that is bactericidal in vitro 
for gram positive organisms including vancomycin-resistant enterococci (Oberholzer 
et al 2005). Experience with daptomycin in the pediatric population is very limited. We 
report a case of a neonate with persistent bacteremia caused by vancomycin-resistant 
enterococcus (VRE) with microbiological cure only after instituting a daptomycin-
containing regimen.
Case report
At 11 days of age a full-term girl with hypoplastic left heart syndrome underwent Stage 
I Palliation (Norwood with Sano modiﬁ  cation) with a 5 mm Gortex shunt placement. On 
post-operative day (POD) 10, she developed fever; blood cultures (BACTEC Peds-plus) 
were taken through a central venous catheter and via venipuncture followed by removal 
and replacement of vascular catheters. Vancomycin was empirically started (Figure 1). 
Both blood cultures grew Enterococcus species. Creatinine was 1.6 mg/dL. On POD 13 
the blood culture isolates were identiﬁ  ed as vancomycin-resistant Enterococcus faecium 
(VRE, susceptibilities in Table 1) and antimicrobial therapy was changed to linezolid 
(10 mg/kg/dose every 8 hours). On POD 15 she became afebrile but blood cultures 
remained positive through POD 18. On POD 16, all vascular catheters were removed and 
replaced. The antimicrobial was changed to quinupristin/dalfopristin (7.5 mg/kg/dose 
every 8 hours) on POD 18. Ampicillin-sulbactam (50 mg/kg/dose every 12 hours) was 
added a day later for possible synergy. The patient remained critically ill. On POD 18 
the patient underwent cardiac catheterization; a restricted Sano shunt was found and 
a stent was placed with improvement. On POD 20 she became febrile. Blood cultures Infection and Drug Resistance 2008:1 10
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obtained on PODs 20, 21, 22, and 23 were negative, but blood 
cultures obtained on PODs 26, 29, and 30 grew VRE. On POD 
30 the antimicrobial was changed to daptomycin at a dose of 
4 mg/kg/dose every 48 hours (serum creatinine, 0.9 mg/dL) 
and rifampin (18 mg/kg/day). Blood cultures obtained on 
PODs 30, 32, 34, 37, 39–41, 43, and 44 remained positive. 
On POD 38 rifampin was discontinued and gentamicin was 
started. One week later doxycycline (2.5 mg/kg/dose every 
12 hours) was added.
Two weeks into daptomycin therapy the serum creatinine 
remained elevated to 0.9 mg/dL and 4 weeks into therapy 
it was 0.6 mg/dL where it remained for the duration of 
treatment. She continued to have positive blood cultures. 
Five days after starting daptomycin, a trough concentration 
obtained 24 hours after a dose was 2.77 μg/mL, determined 
using a validated high performance liquid chromatography 
(HPLC) method at the Center for Anti-Infective Research and 
Development at Hartford Hospital, and the dosing interval was 
reduced to 36 hours. The following day a daptomycin peak 
concentration was 6.19 μg/mL and the dose was increased to 
6 mg/kg every 36 hours. Due to continued positive cultures 
the dosing interval was reduced to 24 hours. Five days later, 
the peak concentration was 31.32 μg/mL. Gentamicin was 
discontinued 1 week later and doxycycline was continued 
until end of therapy with daptomycin. It was not until POD 
45, after receiving the higher dose of daptomycin for 7 days, 
that her blood cultures became persistently negative. She 
received an 8-week daptomycin course including 6 weeks 
after the last positive blood culture. Creatine phosphokinase 
(CPK) concentration was normal on daptomycin treatment 
days 1, 8, and 14. In follow up the patient did well and toler-
ated an additional cardiac surgical procedure.
Discussion
Our patient had persistent VRE bacteremia that was refrac-
tory to multiple antimicrobials and removal and replacement 
of vascular catheters. We presume that endocarditis was 
present (Saiman 2003; Tissieres et al 2003). Her infection 
was unlikely vascular catheter-associated given persistence 
of positive blood cultures despite two changes of the vascular 
catheter. However, the possibility of septic thrombophlebitis 
of a large vein could not be completely excluded; no imaging 
was done speciﬁ  cally to exclude this possibility.
Treatment options for VRE are limited (Torres-Viera 
et al 2004). Linezolid, approved for use in neonates, and 
quinupristin/dalfopristin are bacteriostatic for entercocci 
and were ineffective in our patient. Ampicillin-sulbactam 
and gentamicin were added for possible synergistic killing 
(Matsumura et al 1999; Murray 2000). Daptomycin is a 
new semisynthetic cyclic lipopeptide antibiotic that binds 
the bacterial cell wall membrane and forms pores, followed 
by a calcium-dependent action that increases the membrane 
potential and results in bacterial cell death. A daptomycin-
containing regimen was successful in clearing the bac-
teremia and curing the persistent bloodstream infection. 
Figure 1 Patient course in relation to blood culture results and antimicrobial therapy.
Abbreviations:  Va,vancomycin; Li, linezolid; Amp/Sulb, ampicillin/sulbactam; Quin/Dalfo,quinprisitin/dalfopristin; Rif, rifampin; Da, daptomycin
Table1 Antimicrobial susceptibility for Enterococcus faecium isolate
Antimicrobial Method of 
susceptibility Testing
MIC
(μg/mL)
Susceptibility 
interpretation
Ampicillin Vitek system (VS)*
E-test
32
256
R
R
Gentamicin VS 500 S
Linezolid VS 2 S
Quinupristin/
dalfopristin
VS 0.5 S
Tetracycline/
doxycycline
VS 1 S
Vancomycin VS 32 R
Daptomycin E-test† 1S
Rifampin Disk diffusion Not 
applicable
S
Abbreviations: MIC, mean inhibitory concentration.
*bioMerieux, Durham, NC; †AB Biodisk, Solona, Sweden.
Blood
Culture + +++++ ++ + - - - - + + + ++ ++ + + - + + - - - -- -
POD# 10 15 20 25 30 35 40 45 50 55 60 //80
Va Li Quin/Dalfo
Amp/Sulb
Da 4 mg/kg Daptomycin 6 mg/kg
Rif Gentamicin
DoxycyclineInfection and Drug Resistance 2008:1 11
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Because the patient received short courses of concomitant 
rifampin and gentamicin and a long course of doxycycline 
we cannot exclude the possibility that one or more of these 
antibiotics contributed to the favorable outcome.
Data are limited on the appropriate dosing regimen of 
daptomycin for pediatric patients. In our patient, clearance 
of blood cultures correlated with a dose of 6 mg/kg every 
24 hours. However, our patient had impaired renal func-
tion (serum creatinine concentration of 0.6 mg/dL; normal, 
0.3 mg/dL) and daptomycin is excreted through the kidneys. 
An infant with normal renal function might require more 
frequent administration. We found 4 published reports of 
the use of daptomycin in pediatric patients. Adura et al 
evaluated 16 pediatric patients who received daptomycin at 
a dose of 4–6 mg/kg once daily (except 1 patient with renal 
dysfunction who received 4 mg/kg every 48 hours. All but 
one had infection caused by Staphylococcus aureus and the 
majority improved with the addition of daptomycin (Adura 
et al 2007). In a second report, a 13-year-old male status-post 
bone marrow transplant for aplastic anemia was treated with 
daptomycin for VRE endocarditis at a dose of 8 mg/kg once 
daily (Atkins et al 2006). Study of the pharmacokinetics of 
daptomycin demonstrated faster clearance than in adults. In 
a single-dose study, higher clearance rates and shorter half-
life of daptomycin was observed in children 2–6 years old 
compared with children 7–11 or 12–17 years of age or adults 
(Abdel-Rahman et al 2007). Neonates may require higher 
and more frequent dosing. Two neonates were treated with 
6 mg/kg/dose every 12 hours (Cohen-Wolkowiez et al 2008). 
We observed no adverse effects of daptomycin therapy in our 
patient. Serum CPK was monitored during the ﬁ  rst 2 weeks 
of therapy and not subsequently tested; there was no clinical 
evidence of rhabdomyolysis. When administered to adults it 
is recommended that serum CPK be monitored weekly and 
daptomycin be discontinued if CPK concentration exceeds 
5 times the normal concentration (Schriever et al 2005). 
Successful therapy of our patient with daptomycin suggests 
this agent may be useful for treatment of pediatric patients 
with serious infections caused by VRE. Further studies are 
needed to determine dosing, efﬁ  cacy, and adverse effects of 
daptomycin in pediatric patients.
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